Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Dosage Final > Cell-Based Therapeutics > Flashcards

Cell-Based Therapeutics Flashcards

1
Q

regulated therapies

A

cultured cells
sorted cells
cells in 3D scaffolds
engineered cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

non-regulated therapy example

A

injecting bone cells into bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

criteria to be unregulated
all answers must be YES

A

1) minimally manipulated
2) homologous use
3) HCT/P combined with device or drug that is sterilizing, preserving, or storage agent?
4) the HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

types of cell-based therapies

A

stem cell products
immunotherapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

stem cells and stem cell derived products

A

do not involve immune cells
stem cell therapy is unspecialized, self-renewal, and pluripotency
example –> stem cell transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

immunotherapies

A

involves immune cells
example –> cancer vaccine and cell-based immune therapies (can be naive or gene based); CAR-T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

components of a CAR-T terapy

A

CAR –> chimeric antigen receptor (gene)
T –> T cells
cells are removed, genetically engineered, expanded and delivered back to the patient (who are pre-conditioned with chemotherapy to restrain immune response)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

autologous cell-based therapy

A

cells from your own body
no graft vs host disease
higher doses feasible
harder to source, immune-compromised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

allogenic cell-based therapy

A

cells from a different donor
easier to source, off the shelf
can induce graft vs host disease and/or immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some problems you might think could arise when developing drugs that target a single tumor antigen?

A

on target, off tumor effects (cells target the correct antigen but one expressed on tissues other than the target cancer, results in severe toxicities)
fratricide (cells target an antigen that is expressed on themselves)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the main safety issues associated with cell-based gene therapies?

A

tumor evasion
neurotoxicity due to immune cell activity (potentially fatal)
cytokine release syndrome (CRS)
graft vs host disease
toxicity assocaited with viral genomic DNA (if viral CARs are used)
persist for an extended period and produce a sustained effect –> increases/prolongs ADRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tumor evasion

A

escape of cancer cells from recognition and killing by immune cells resulting in clinical resistance to treatment
tumor antigens are not recognized by immune response –> poorly immunogenic
tumors are resistant to or inhibit immune cytotoxic responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how to prevent cell persisting /sustained effect

A

engineering of suicide switches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are two reasons why cell-based therapies have been more successful (and approved by the FDA) for blood cancers, but not solid tumors?

A

solid tumors –> heterogeneous and have immunosuppressive factors (metabolites, soluble molecules)
immune cells –> infiltration is low, in solid tumors they are dysfunctional

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is one way to clinically mitigate or manage cytokine release syndrome?

A

avoid steroids (could impact CAR-T cells)
antibodies against toxin and cytokines (IL6)
use cells that induce no or limited CRS (NK cell)
through hemofiltration (to filter out cytokine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

drug substance

A

gene vector (engineered molecular component)
example –> CAR or gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

drug product

A

cryopreserved engineered cell (immune cell and gene)
example –> CAR-T/NK cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ADCC

A

antibody dependent cell-mediated cytotoxicity
when an antibody interacts with CD16 on NK cells to stimulate activation to kill

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

potential risk of cell-based therapies

A

graft vs host disease disease
cytokine release syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

graft vs host disease

A

arise when patients infused with exogenous cells or transplanted with donor tissue recognize these transplants as foreign and react unfavorably

21
Q

cytokine release syndrome

A

systemic inflammatory response
results in the release of a high number of pro-inflammatory cytokines that attack the patient’s immune system

22
Q

lymphodepletion

A

chemotherapy to prime patient for cell transfer by weakening the immune system to avoid rejection
the process of removing immunosuppressive subsets of immune cells (like Tregs) from the patient

23
Q

common agent used in lymphodepletion

A

fludarabine

24
Q

fludarabine

A

inhibits DNA polymerase (thus synthesis)
immune cells accumulate F-ara-ATP (the active metabolite) –> makes them sensitivite to lymphodepletion
dosed as > 25-40 mg/m^2

25
Q

ADME of cell therapy in comparison to small molecule drugs

A

cells are not secreted but remain in the system
long term –> divide inside recipient

26
Q

challenges with CAR-T manufacturing

A

sterilization of final product not possible (aseptic processing key)
patients are very sick (so they need product quickly)
cell variability requirements cannot always be met
donor cells cannot always expand optimally, cells are exhausted
complex logistics –> freeze/thaw necessary mulitiple times

27
Q

centralized cell therapy manufacturing

A

PROS –> easier to scale up, central process control and batch records, lower material cost
CONS –> complex logistics, longer time to patient, product must be frozen

28
Q

decentralized cell therapy manufacturing

A

PROS –> quicker, closer to consumer; process is ready for infusion and dose not need to be shipped
CONS –> cannot be scaled up; costly

29
Q

cryopreservation

A

example agent –> DMSO (most commonly used)
process of freezing of the cell therapy drug product
required as cell therapy products cannot be lyophilized easily
enables shipment and storage of the drug product prior to administration

30
Q

Tocilizumab (IL6)

A

drug commonly use to mitigate cytokine release syndrome

31
Q

extracellular region of CAR

A

antigen binding domain that binds to cancer cell

32
Q

naive cell therapies

A

unmodified immune cells (TILs, hematopoietic stem cell transplants)
just give cell to patient, no engineering

33
Q

How can immune cells be redirected to attack pathogens?

A

through engineering synthetic receptors that can recognize antigens present on specific cancers
releasing proteins (cytotoxic granules) that kill target cells

34
Q

types and sources of cell-based therapies

A

peripheral blood
core blood
cell lines
induced pluripotent stem cells

35
Q

peripheral blood characteristics

A

autologous transfer
patient-specific
10% NK/T cells

36
Q

core blood characteristics

A

allogenic
can be cryopreserved
30% NK/T cells

37
Q

cell lines characteristics

A

commercially available
allogenic
not like human cells

38
Q

induced pluripotent stem cells characteristics

A

allogenic through gene editing
can be cryopreserved
off the shelf

39
Q

types of adoptive cell-based immunotherapies

A

donor matching
native immune cells (activated)
TIL (tumor infiltrating lymphocytes)
TCR (T-cell receptors)
CAR-T or CAR-NK

40
Q

donor matching adoptive cell-based immunotherapies

A

either haploidentical (half matched so mom, dad, child) or HLA-matched (fully matched so siblings, unrelated, or core blood)

41
Q

native immune cells (activated)

A

kill cancer without antigen dependent
natively expanded outside of the body
can be engineered with CARs or infused after expansion without engineering
participate in ADCC, T cells do not
generally do not cause CRS (unlike T cells)
no rejection

42
Q

TIL (tumor infiltrating lymphocytes)

A

lymphocytes that have infiltrated a tumor and can recognize specific antigens
mostly CD8+ T cells which can produce cytokines and mediate tumor killing
extracted from the tumor and reinfused back into the patient after expansion

43
Q

how are genes most commonly engineered into cells?

A

through viruses because they have highest efficiency, are permanent, and potentially toxic

44
Q

basic structure of CAR-T cell therapies

A

extracellular antigen binding domain, transmembrane domain, and intracellular/costimulatory domain

45
Q

role of extracellular antigen binding domain

A

bind to cancer cell

46
Q

role of transmembrane domain

A

anchor and orientation to facilitate interaction with T cell surface proteins

47
Q

role of intracellular/co-stimulatory domains

A

send cytotoxic/killing/activation signals

48
Q

first two FDA-approved CAR-T cells therapies are targeted against blood cancer

A

Leukemia
Lymphoma

49
Q

how is CRS commonly treated?

A

with IL-6 antibody

Dosage Final (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions